US Food and Drug Administration officials are interested in testing the real-time oncology review program in other disease areas as part of the next prescription drug user fee cycle.
PDUFA VII Could Expand US Real-Time Review Beyond Oncology
A proposed pilot program would offer for “split submission and review” of some application sections in other disease areas. Discussions also touch on concept of a CDER-CBER RWE committee.
